Female Pelvic Medicine & Reconstructive Surgery · 2019 · 47 citations · 41 references
MedicineSurgeryUrologyGastroenterologyUrodynamicsUrogenital SurgeryColorectal SurgeryPelvic AssessmentPelvic Floor DisordersPelvic Floor HealthPelvic Floor ReconstructionPelvic Organ ProlapseIncontinence Severity MeasurementPatient-reported Outcome ReportingPatient-reported Outcomes In ReconstructionPelvic Floor Symptom AssessmentReconstructive Pelvic Floor SurgeryValidated Symptom Questionnaires
The Pelvic Floor Disorders Consortium (PFDC) is a multidisciplinary organization of colorectal surgeons, urogynecologists, urologists, gynecologists, gastroenterologists, physiotherapists, and other advanced care practitioners. These practitioners, along with their respective societies, research foundations, and committees, are committed to enhancing the care of patients with pelvic floor disorders. The PFDC’s goal is to collaborate through clinical care and research to develop and evaluate educational programs, create clinical guidelines and algorithms, and promote overall quality of care in this unique population. The recommendations arising from this effort below represent the work product of the PFDC Working Group on Patient-Reported Outcomes. The objective of this workgroup, which included specialists from 12 countries, was to generate inclusive, rather than prescriptive, guidelines for all practitioners, irrespective of discipline, in the care and treatment of patients with pelvic floor disorders. STATEMENT OF THE PROBLEM The patient-reported outcome (PRO) is defined as a report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else.1 Beginning with the introduction of the Karnofsky performance status scale in 1948,2 health-related quality of life (HRQoL) has become an increasingly important metric in the field of health care research. The growing prominence of HRQoL signifies a shift in focus from clinical outcomes related solely to survival and complications, to outcomes that include the patient’s perspective. Studies have shown that clinicians’ assessments of outcomes that matter often differ significantly from outcomes reported by patients. A considerable disconnect can occur between what the observer deems important versus what the patient considers important in terms of symptom management and the balance between relief and quality of life.3,4 The importance of PROs is evident in the wide recognition they have received by major health care providers and organizations. For example, the US Food and Drug Administration enhanced its scrutiny of available instruments5 following the publication of guidelines for PRO instruments used as effectiveness end points in clinical trials.1 Likewise, the National Health Service (NHS) in the United Kingdom mandated funded providers to report PRO measures for certain elective surgical procedures. Finally, many clinicians now use PROs to follow their patients over time and between treatments to help guide patient care.6 To function effectively as a quality-of-care instrument, the PRO must be accurately communicated and compared. This is especially critical for surgical interventions. Compared to other areas of medicine, treating pelvic floor disorders relies heavily on patient-reported symptoms, and frequently, the outcomes cannot be measured, compared, or quantified by objective tests or imaging. Hence, to ensure clear communication between providers and researchers, validated instruments have been created to reliably measure patient-reported functional status. Additionally, these instruments must have reasonable sensitivity and specificity to detect changes in patient condition over time, as well as differences between patients and patient populations. Furthermore, to achieve optimal outcomes in patients with pelvic floor disorders, a consensus is required to identify the best available validated instruments for capturing patient-reported symptoms, such as fecal incontinence, urinary incontinence, constipation, lower urinary tract symptoms, and sexual dysfunction. In general, a common language is desirable because it fosters accurate interpretation and comparison of treatments and facilitates pooling of data for meta-analysis and systematic review. Unfortunately, the failure of many recent attempts to achieve data consolidation in this area are due to the lack of consensus among clinicians and researchers regarding which instrument(s) should be used and reported in research publications.7 This document describes the process the PFDC working group followed to reach consensus as to which of the many existing validated instruments should be recommended to health care providers, irrespective of discipline (ie, colorectal surgeon, urogynecologist, urologist, gastroenterologist, or physiotherapist). After reviewing all of the major existing instruments and generating a standardized list of those most accurate and practical to use, the working group created a common initial patient assessment measure for every clinical setting, regardless of which specialist saw the patient first. Ultimately, consensus was reached regarding the best tool for each condition. The agreed upon battery of recommended validated instruments was ultimately labeled IMPACT (Initial Measurement of Patient-Reported Pelvic Floor Complaints Tool). The panel concurred that, even though it may be possible to identify a better instrument for a given symptom (eg, fecal incontinence versus urinary incontinence), not having a standardized instrument was a hindrance to large-scale multidisciplinary collaboration in clinical and scientific research. It also hindered communication between experts about specific patients and the perceived severity of their condition. The members believed strongly that a simple consensus document, such as IMPACT, could remedy the situation and foster progress toward a common language for patient-reported pelvic floor disorder clinical outcomes. METHODOLOGY This document was created at the initiative of the Pelvic Floor Disorders Consortium (PFDC) Working Group on Patient Reported Outcomes. The PFDC is composed of clinicians with demonstrated expertise in the care and treatment of pelvic floor conditions. The Working Group on Patient-Reported Outcomes was created by enlisting Pelvic Floor Consortium volunteers. Invitation criteria included leadership in the field of pelvic floor disorders with academic scholarship and history of cross-disciplinary collaboration. Literature Search An organized search of MEDLINE, PubMed, EMBASE, and the Cochrane Database of Collected Reviews was performed on July 1, 2018, and repeated on September 1, 2018. Retrieved publications were limited to the English language, but no limits on year of publication were applied. The search terms also included “fecal incontinence, urinary incontinence, constipation, lower urinary tract symptoms in men and women, and sexual dysfunction in men and women.” The search strategies used “patient reported outcomes,” “validated instruments,” and “questionnaires” as primary search terms. Other terms included “fecal incontinence,” “constipation,” obstructed defecation syndrome,” “intestinal function,” “bowel function,” “gastrointestinal symptoms,” “sexual function in men,” “sexual function in women,” “urinary incontinence,” “lower urinary tract symptoms,” “bladder dysfunction,” and “quality of life.” Directed searches of the embedded references from the primary articles were also performed in certain circumstances. Thus, 3211 references were retrieved by the working groups, and most were excluded to arrive at 182 instruments. Criteria for inclusion were instruments that underwent score validation, scores that were commonly used in clinical practice, and scores that have been demonstrated to have ability to discriminate well by disease populations. Thus, from 182 articles, each workgroup arrived at 10 to 15 final articles selected for further detailed analysis. Preliminary Workgroup Considerations and Deliberations Six multidisciplinary workgroups were created, each assigned to investigate a specific symptom: fecal incontinence, constipation, urinary incontinence, lower urinary tract symptoms, male sexual function, and female sexual group the 10 to 15 in the on sensitivity to of and of use in the to and The by criteria to reach a consensus regarding the to instruments that further by the In and members instrument to be also the instruments were for In the workgroup members also the of for each instrument, which as a of Pelvic Floor Consortium The Pelvic Floor Consortium on in It included than experts from 12 and included colorectal and The was funded by the of and and the These experts to in treating pelvic floor disorders, but not limited the of and and the were from the the of and the of Pelvic The at the consensus all of the each of the in this ultimately instrument(s) for each of were to the final consensus document and reached consensus regarding the and was defined as by or of the consensus was not the workgroups performed research and to A was to final on the the of the consensus panel in The final recommended list of validated instruments was IMPACT (Initial Measurement of Patient-Reported Pelvic Floor Complaints Tool). The IMPACT is a of all the by the experts in each in their An IMPACT was also created to of the final IMPACT tool was on and the was created, the to its was and for by the of and Pelvic Floor Disorders This is to develop clinical recommendations on colorectal pelvic floor disorders on best available The the document and it to the for final for and were also given by the of the of and the of Pelvic of The document was also by the of the of to the recommendations for female patients not on the male instruments because their members not Measurement of The the use of the and the The use of assessment of the severity of fecal incontinence, also of the of and on the severity of fecal of 12 colorectal and as workgroup The initial instruments by the workgroup members are in 1, agreed that instruments should have the to the pelvic floor disorders and the best of and that the severity of fecal incontinence and are because this often symptom to with fecal incontinence instruments were over instruments. The workgroup reached consensus that instruments be for the Pelvic Floor Consortium the the and and the These instruments were over other instruments on of use, ability to in symptoms, and recognition and In the of scale was selected as the is a tool that severity of fecal incontinence a with of and It has been used to evaluate the of treatments for fecal incontinence, and it is validated and It is a score on a of colorectal and patient It is a tool because it with patient of symptoms related to the not or the of can be and to in a clinical The and was recommended because it is the most validated instrument for the severity of fecal incontinence by the It is the instrument that the of which was for the severity of by a of the organized by the National of Thus, it the severity of fecal incontinence, fecal and constipation, in to the instrument which is for a clinical the severity of fecal incontinence can be and with The of this instrument has limited its use in the The was in and to of incontinence with use of a and to the severity score It was as a clinical but research has been to it and to its and sensitivity to The for of and is the most used instrument in the as of September It is also by patients and has been shown to have a to of The can be an This instrument to the symptom of fecal of or on quality of The is to and the In this score also symptoms of and the of on the symptoms of incontinence, it in The as than 15 to reach the this is on reported they could defecation for is validated and to it is used in the of treatments on fecal incontinence and the severity of incontinence in patient with as of The of is the and in comparison to these measures the tool to use the at the PFDC was than consensus that the final measure to be to for was also reached that the of incontinence was not because is commonly to and rather than a of Ultimately, these to the of and The also reached consensus that the final tool should a of the of on the severity of The this a was that to patients This from consensus as the final recommended tool in The many because it for a clear and of disease but the lack of measure it from the consensus to become the final recommended tool in the the workgroup used the from the PFDC to the and This group and reached a consensus that a of and could be used to the of symptoms of of quality of and practical of data in clinical practice, the goal for multidisciplinary Measurement of The the use of the Patient of and It was that use of was to assessment of the severity of the of defecation constipation, and to and of the of this condition. of colorectal and as workgroup The initial instruments by the workgroup members are in agreed that instruments should have the to the pelvic floor disorders and the best of and instruments were over instruments. The workgroup among a of many of in the and ultimately reached consensus to instruments the Pelvic Floor Consortium and Patient of and Outcomes Measurement In Patient of of was selected as the the Pelvic Floor Consortium the and of the instruments were to the The was to be the most of instruments with and to Additionally, was the instrument to the by to be a for and also between functional and a fecal incontinence the group its to be for Additionally, severity is not and to has not been a was the group that the instrument was not validated in its The no is the instrument available and was for its and with comparison to US an to a multidisciplinary group such as the is urinary incontinence on the was that and symptoms commonly in this required A recent demonstrated that the scale was not to Finally, the was to be validated and used treatment and with over time and ability to between treatment and The with this instrument, because it has been used in clinical for the between symptoms with the instrument and is due to that symptoms could be and is no (eg, comparison with objective of pelvic floor dysfunction or to these this instrument not for the for to which they was an in this population. Additionally, was for the lack of a or with which to the working group the instruments to the other members of the that that the in the panel the workgroup further that the been validated instrument and PFDC members that the by the and were for patients on that specific symptoms and the by the have not been validated in to In of the from the PFDC the working group ultimately and reached a consensus that a of the and the of for all PFDC with an toward Measurement of The the use of the of the in the final IMPACT tool to of and incontinence and its of to patients. of colorectal surgeons, urologist, urogynecologists, and pelvic floor as workgroup The initial instruments by the workgroup members are in agreed that instruments should have the to the pelvic floor disorders and the best of and instruments were over instruments. The workgroup reached consensus that instruments be the PFDC The scores were the on and These scores were because they were each well heavily and to The scores that were were on urinary incontinence quality of life rather than symptom a of symptoms other than or were limited to specific of The their to the members of the in an It was that the were better for the assessment of dysfunction Thus, and were as the symptom instruments. instruments were selected for their sensitivity to and and use on 1, 2018, and on September In the many its for men and women, its inclusion of a symptom and its assessment of the of of the that were included that it a of symptoms and of of symptom and the inclusion of a Furthermore, the is a commonly used instrument in clinical work and research. the consensus the and dysfunction a final and the was as the most instrument for symptoms for clinical and research The and the of symptoms with severity of symptoms and symptom Furthermore, the a score that has been demonstrated to be to with treatment and with in and The the of lower urinary tract function in patients by In women, the the use of the on of In the the use of the of colorectal surgeons, urologists, and as workgroup The initial instruments by the workgroup members are in The inclusion criteria for instruments were and the were as to each tool severity of symptoms was given to that were and could be were well and could be to the population. this it clear that many of the validated for dysfunction were at specific men and patients with The in the instruments the of differences and disease in the of dysfunction. the were in terms of they could be used to and to a population. many validated instruments not for severity of symptoms and a score was to the ability of a to these These scores were or all the could be used to severity of symptoms and A was of the of each from all and the scores were in of These data were at the Pelvic Floor Consortium to from the on to best the tool most to be used by most The selected recommended by the at the included the and the The experts also at the which they as their instrument of for the of urinary The also has a about but the that a be to for these this the dysfunction and urinary incontinence on the final of instruments. no other have been validated in the was for men and the was for are and for the severity of symptoms and in each These instruments include regarding urinary and The has been used in male dysfunction research for many because it the symptom as of its September The has been validated in in a and in a to in the initial the in their data that the was not to be in This tool has not been validated in in it was that the is better for dysfunction in women, because it is a and tool on September of of The inclusion of the of the Pelvic Floor in the final IMPACT tool to for of the of to patients from their and pelvic of The workgroups not focus on a detailed of all existing that measure all pelvic floor disorders. to these instruments the Pelvic Floor Consortium and received that the of tool is the most commonly used instrument among the The tool could to the of symptoms of fecal incontinence on quality of the group that, be to clinicians to focus their treatment or research on patients symptoms of fecal incontinence, it was to the as a recommended for clinical use, and its the final IMPACT tool the Pelvic Floor Consortium with consensus that the Patient of of tool could be to clinicians clinical care or research in patients have they the instrument was to inclusion in the IMPACT The experts also that many patients with pelvic floor disorders may report symptoms of pelvic floor disorders and that the at the not the of pelvic floor also that, or symptoms may be their could have a on the patient’s quality of life and that measure of the of by symptoms be a to the IMPACT This to a and on the Pelvic Floor The was because of its in the The was from a of the instrument to measure the of common pelvic symptoms and the to which these symptoms their The has been shown to be with its and to that the inclusion of a that of by pelvic floor symptoms be a to the IMPACT This to inclusion of the of the Pelvic Floor in the final IMPACT in The the of of 15 is a a of specific validated of the of to at measure male function 1, and and function and its on quality of life of colorectal surgeons, urologists, and as workgroup The initial instruments by the workgroup members are in the a was to include those instruments with of and In instruments were that for and this group of the workgroup reached consensus that instruments be the Pelvic Floor Consortium the of the Health for and the The is a instrument with HRQoL in validated urinary function function sexual function and function each of which can be This has been in the are to sexual The of this and of is also its in that the workgroup it was to in clinical of a research of this is that it has been validated in men with which may its to other male patients with dysfunction. The is the most instrument for male sexual function as of and a of 15 The is a instrument with validated function function sexual and overall Other include that it has been validated in 10 and it was validated in an of men with dysfunction to a of the treatment of The or Health for is and in the scientific as of The from the the the was validated in male patients with dysfunction due to a of The of and 15 from the These are from the function and and the The other function, sexual and overall are not in the the function was shown to have in the assessment of male sexual The of the included in to the regarding dysfunction to in the of dysfunction the Pelvic Floor Consortium the and of the instruments were to the The experts that the was to in clinical as an initial assessment tool for than pelvic floor The was for its but they its focus on dysfunction many colorectal patients may also changes in The a that measures these symptoms with The the overall to be and ultimately that it is to score that the final IMPACT tool should include the to function 1, and and function that the other are in patients with pelvic floor disorders and could be at the for the of in The the of sexual function in to the patient In with pelvic floor disorders, the the Pelvic of and 12 not In without pelvic floor disorders, or is a the the of colorectal surgeons, urogynecologists, and as workgroup The initial instruments by the workgroup members are in to the a was that instruments with of and be In 12 instruments were that for and To achieve this the each instrument the criteria used by all other In the instruments were the following used for validation, in pelvic floor disorders assessment of female sexual function female and male sexual function in assessment of female sexual and quality of life assessment of sexual function in without or not important and of validated as well as and The panel also the selected instruments were available at no this group of the workgroup reached consensus that severity instruments be the Pelvic Floor Consortium the Pelvic the Pelvic and The Pelvic is the of the female sexual function to sexual function in with The with 12 is for of the is a The is of the most for with pelvic floor disorders and it has validated in many The of to many other sexual function is that it excluded were not this was related to lack of or their pelvic floor disorders. Furthermore, was not validated in with Pelvic is the of to the of and The is a validated of female sexual function that can be used in are not in not 12 in The is working on validated many The is the of a is a sexual function that has demonstrated and in a of its use in it is it for use in clinical The is a of in and The of the this is best for sexual function is not the primary end but a end and is a a at the consensus the was further to the and These patient populations. is a validated that with pelvic floor disorders. It is further because it sexual due to pelvic floor disorder or other In is a on September and instrument that has been validated in and women, not validated in with pelvic floor disorders The tool a assessment of female sexual function and dysfunction. The comes in a and The was and to the as well as the and was to be and to Ultimately, no consensus was reached at the between the use of the It was to for clinical that care for with pelvic floor disorders. For clinicians to measure and female sexual function the pelvic floor the was recommended of a IMPACT (Initial Measurement of Patient-Reported Pelvic Floor IMPACT can be used to measure and score the severity of common pelvic floor It all of the instruments recommended in this document in their further is function instruments included in the IMPACT can be the IMPACT be required for the IMPACT to of The Pelvic Floor Consortium reached consensus that it be important for clinicians to strongly all of the pelvic floor as of their regardless of the Ultimately, recommended the of a list of agreed upon instruments that could be labeled this tool IMPACT (Initial Measurement of Reported Pelvic Floor The included in the IMPACT are in of for in the IMPACT (Initial Measurement of Patient-Reported Pelvic Floor and the experts that a tool of this should of no than to the final is significantly for men and to for Furthermore, it especially in the function The and not as This the experts to a of the function the IMPACT The all the in the but patients the function In the function have a of from instrument to instrument, the patient is to the of possible a of instruments through a from of score for a no is the function tool is Considerations included in the tool are further in the these the of function was from to 12 and the overall measures for and for men The of the scores are further in These instruments are and to use for clinical use and in clinical may be for research and these are in IMPACT (Initial Measurement of Patient-Reported Pelvic Floor Complaints function, are included in IMPACT (Initial Measurement of Patient-Reported Pelvic Floor Complaints function, are included in IMPACT (Initial Measurement of Patient-Reported Pelvic Floor Complaints function, are included in of the for in the IMPACT (Initial Measurement of Patient-Reported Pelvic Floor A reasonable consensus was reached by the Pelvic Floor Disorders Consortium on the pelvic floor symptom and patient-reported instruments and that should be recommended in a clinical and as a measure in clinical research common pelvic floor symptoms, a and These can be with and detailed about a condition is to The for and of at the for members of The Pelvic Floor Disorders Consortium Working Group on Patient-Reported Outcomes. in than workgroup and are of the Pelvic Floor Disorders Consortium Working Group on Patient-Reported Outcomes
41